Is checkpoint inhibitor pneumonitis underreported in patients with advanced non-small cell lung cancer (NSCLC) on PD-1 inhibitor monotherapy?

被引：2
|
作者：
Spieler, Benjamin Oren
Lopes, Gilberto
Dal Pra, Alan
Diwanji, Tejan
Yechieli, Raphael
Freedman, Laura M.
Mihaylov, Ivaylo
机构：
[1] Univ Miami, Miller Sch Med, Miami, FL 33136 USA
[2] Univ Miami Hlth Syst, Miami, FL USA
[3] Univ Miami, Sylvester Comprehens Canc Ctr, Miami, FL USA
[4] Univ Miami, Parkland, FL USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2020年 / 38卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
9579
引用
收藏
页数：2
相关论文
共 50 条
  • [41] Clinical characteristics and therapeutic effects of checkpoint inhibitor-related pneumonitis in patients with non-small cell lung cancer
    Li Pang
    Mei Xie
    Xidong Ma
    Aiben Huang
    Jialin Song
    Jie Yao
    Hui Deng
    Duchao Zhang
    Xuelei Zang
    Fangping Ren
    Jie Gao
    Chongchong Wu
    Yuanyong Wang
    Xin Zhang
    Xinyu Bao
    Lei Pan
    Xinying Xue
    BMC Cancer, 23
  • [42] The prognostic impact of severe grade immune checkpoint inhibitor related pneumonitis in non-small cell lung cancer patients
    Sun, Ni
    Li, Ru
    Deng, Haiyi
    Li, Qingyang
    Deng, Jiaxi
    Zhu, Yue
    Mo, Wenwei
    Guan, Wenhui
    Hu, Minjuan
    Liu, Ming
    Xie, Xiaohong
    Lin, Xinqing
    Zhou, Chengzhi
    FRONTIERS IN ONCOLOGY, 2024, 14
  • [43] Clinical applications of radiomics in non-small cell lung cancer patients with immune checkpoint inhibitor-related pneumonitis
    Shu, Yang
    Xu, Wei
    Su, Rui
    Ran, Pancen
    Liu, Lei
    Zhang, Zhizhao
    Zhao, Jing
    Chao, Zhen
    Fu, Guobin
    FRONTIERS IN IMMUNOLOGY, 2023, 14
  • [44] Predictive factors and prognosis of immune checkpoint inhibitor-related pneumonitis in non-small cell lung cancer patients
    Liu, Xiaoyu
    Hao, Na
    Yang, Shuangning
    Li, Jieyao
    Wang, Liping
    FRONTIERS IN ONCOLOGY, 2023, 13
  • [45] Clinical implications of bronchoscopy for immune checkpoint inhibitor-related pneumonitis in patients with non-small cell lung cancer
    Nishiyama, Osamu
    Shimizu, Shigeki
    Haratani, Koji
    Isomoto, Kosuke
    Tanizaki, Junko
    Hayashi, Hidetoshi
    Yamazaki, Ryo
    Oomori, Takashi
    Nishikawa, Yusaku
    Sano, Akiko
    Nakagawa, Kazuhiko
    Tohda, Yuji
    BMC PULMONARY MEDICINE, 2021, 21 (01)
  • [46] Clinical characteristics and therapeutic effects of checkpoint inhibitor-related pneumonitis in patients with non-small cell lung cancer
    Pang, Li
    Xie, Mei
    Ma, Xidong
    Huang, Aiben
    Song, Jialin
    Yao, Jie
    Deng, Hui
    Zhang, Duchao
    Zang, Xuelei
    Ren, Fangping
    Gao, Jie
    Wu, Chongchong
    Wang, Yuanyong
    Zhang, Xin
    Bao, Xinyu
    Pan, Lei
    Xue, Xinying
    BMC CANCER, 2023, 23 (01)
  • [47] Characteristics, incidence, and risk factors of immune checkpoint inhibitor related pneumonitis in patients with non-small cell lung cancer
    Cho, Jun Yeun
    Kim, Junghoon
    Lee, Jong Seok
    Kim, Yu Jung
    Kim, Se Hyun
    Lee, Yeon Joo
    Cho, Young-Jae
    Yoon, Ho Il
    Lee, Jae Ho
    Lee, Choon-Taek
    Park, Jong Sun
    LUNG CANCER, 2018, 125 : 150 - 156
  • [48] Clinical implications of bronchoscopy for immune checkpoint inhibitor-related pneumonitis in patients with non-small cell lung cancer
    Osamu Nishiyama
    Shigeki Shimizu
    Koji Haratani
    Kosuke Isomoto
    Junko Tanizaki
    Hidetoshi Hayashi
    Ryo Yamazaki
    Takashi Oomori
    Yusaku Nishikawa
    Akiko Sano
    Kazuhiko Nakagawa
    Yuji Tohda
    BMC Pulmonary Medicine, 21
  • [49] Non-Invasive Detection of Predictive Biomarkers for PD-1 Inhibitor Treated Non-Small Cell Lung Cancer Patients
    Stensgaard, S.
    Thomsen, A.
    Dissing, J. G.
    Knudsen, S. H.
    Meldgaard, P.
    Sorensen, B. S.
    JOURNAL OF THORACIC ONCOLOGY, 2022, 17 (09) : S381 - S381
  • [50] INCIDENCE AND GRADE OF PNEUMONITIS IN ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC) PATIENTS TREATED WITH ANTI-PD1 ANTIBODIES
    Yam, A. O.
    Mersiadis, A.
    Gao, B.
    Hui, R.
    Nagrial, A.
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2016, 12 : 71 - 72
12345